# EDGAR Filing Document

**Accession Number:** 0001690585
**File Stem:** 0000000000-26-001090
**Filing Date:** 2026-1
**Character Count:** 2317
**Document Hash:** cb5032feb9363beb7be1d35804cf0cfc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-001090.hdr.sgml**: 20260422

**ACCESSION NUMBER**: 0000000000-26-001090

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260129

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dianthus Therapeutics, Inc. /DE/
- **CENTRAL INDEX KEY:** 0001690585
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-293014

**BUSINESS ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 929-999-4055

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Magenta Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20161121
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-26-027273

## Text-Extract

```

                                                           January 29, 2026

Marino Garcia
Chief Executive Officer
Dianthus Therapeutics, Inc.
7 Times Square, 43rd Floor
New York, NY 10036

       Re: Dianthus Therapeutics, Inc.
           Registration Statement on Form S-3
           Filed January 28, 2026
           File No. 333-293014
Dear Marino Garcia:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tim Buchmiller at 202-551-3635 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Melanie E. Neary, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._